The Patent Finder

Encysive Pharmaceuticals, Inc.

Also on record
Records under this name other than patents Encysive Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Encysive Pharmaceuticals, Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 6,972,296Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
Term ended
Term ended May 5, 2020 · USPTO record
Term endedTerm ended May 5, 2020USPTO record
US 6,194,448N, N-disubstituted amides that inhibit the binding of integrins to their receptors
Term ended
Term ended Oct 14, 2019 · USPTO record
Term endedTerm ended Oct 14, 2019USPTO record
US 6,262,084Compounds that inhibit the binding of integrins to their receptors
Term ended
Term ended Oct 14, 2019 · USPTO record
Term endedTerm ended Oct 14, 2019USPTO record
US 6,096,773Compounds that inhibit the binding of integrins to their receptors
Term ended
Term ended Apr 15, 2019 · USPTO record
Term endedTerm ended Apr 15, 2019USPTO record
US 7,812,038Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
Lapsed on the fee record
Ended Oct 12, 2018 · USPTO record
Lapsed on the fee recordEnded Oct 12, 2018USPTO record
US 6,432,994Sulfonamides for treatment of endothelin-mediated disorders
Term ended
Term ended Apr 28, 2017 · USPTO record
Term endedTerm ended Apr 28, 2017USPTO record
US 6,030,991Benzenesulfonamides and the use thereof to modulate the activity of endothelin
Term ended
Term ended Dec 6, 2016 · USPTO record
Term endedTerm ended Dec 6, 2016USPTO record
US 8,178,699Modulators of CCR9 receptor and methods of use thereof
Lapsed on the fee record
Ended May 15, 2016 · USPTO record
Lapsed on the fee recordEnded May 15, 2016USPTO record
US 6,723,711Propanoic acid derivatives that inhibit the binding of integrins to their receptors
Lapsed on the fee record
Ended Apr 20, 2016 · USPTO record
Lapsed on the fee recordEnded Apr 20, 2016USPTO record
US 6,686,382Sulfonamides and derivatives thereof that modulate the activity of endothelin
Lapsed on the fee record
Ended Feb 3, 2016 · USPTO record
Lapsed on the fee recordEnded Feb 3, 2016USPTO record
10 of 42 patents shown.
Pro members see all 42.
Pro members: see all 42 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited